Business

According to Asthmapolis, the company has raised $5 million in Series A financing from The Social+Capital Partnership (“Social Capital”) that it will use to "deliver new innovations and services for its comprehensive solution of sensors, leading mobile technology and personalized support, extending its reach to the more than 50 million people living with chronic … [Read more...] about Asthmapolis raises $5 million

Actavis says that it will launch 0.25 mg and 0.5 mg vials of its generic budesonide inhalation suspension immediately after the United States District Court for the District of New Jersey ruled that the products do not infringe AstraZeneca's patents on Pulmicort Respules. Actavis (then Watson) received FDA approval for its ANDA for the 0.25 and 0.5 mg strengths of the … [Read more...] about Actavis plans to launch generic version of Pulmicort Respules after favorable court ruling

Inhalation experts from the Woolcock Institute of Medical Research and the University of Sydney have launched a new company called Pulmatix to provide analytical services ranging from evaluation of APIs and formulations in respiratory cells to formulation and device design optimization. Directors of the new company are Paul M. Young, Daniela Traini, Judy Black, and … [Read more...] about New inhalation testing and consulting company launched in Australia

Savara Pharmaceuticals has received additional funding for Phase 2 development of its AeroVanc vancomycin inhalation powder for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in cystic fibrosis patients. The company brought its Series B financing to a total of $16 million after closing a $7.4 million second tranche and has also received … [Read more...] about Additional funding for Savara’s AeroVanc

Pearl Therapeutics was awarded the 2013 Drug Delivery Partnerships (DDP) Innovation Award for its co-suspension formulation technology, according to the company. The company is developing several metered dose inhalation products using the technology. President and CEO Chuck Bramlage said, “We truly appreciate this award by our peers in the drug delivery industry. … [Read more...] about Pearl Therapeutics wins Drug Delivery Partnerships Innovation Award

The University of East Anglia (UEA) Medical School will fund research to adapt a MRSA-specific antibiotic being developed by Procarta Biosystems into a nasal spray for decolonization of patients before major surgery, according to Procarta. The company says that use of the spray against methicillin-resistant Staphylococcus aureus (MRSA) infections "promises to speed … [Read more...] about University of East Anglia to team with Procarta on anti-MRSA nasal spray

OptiNose has selected Pharma Tech Industries (PTI) to fill capsules, load cartridges, and package completed delivery systems for NDA batches of its dry powder intranasal sumatriptan, according to Pharma Tech. In November 2012, OptiNose announced positive results from a Phase 3 study of the product, which is delivered using the company's bi-directional nasal device. … [Read more...] about Pharma Tech selected for dry powder intranasal product

Prevacus, Inc., a 2012 spin-out from Florida State University, has entered into an agreement with The Institute for the Commercialization of Public Research for funding to support clinical development of Prevasol nasal spray. According to the company, Prevasol "utilizes Neurosteroids to improve behavioral outcomes of brain injury (working memory, sensory … [Read more...] about Developer of nasal spray for traumatic brain injury gets funding